DE69726878T2 - UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE - Google Patents

UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE Download PDF

Info

Publication number
DE69726878T2
DE69726878T2 DE69726878T DE69726878T DE69726878T2 DE 69726878 T2 DE69726878 T2 DE 69726878T2 DE 69726878 T DE69726878 T DE 69726878T DE 69726878 T DE69726878 T DE 69726878T DE 69726878 T2 DE69726878 T2 DE 69726878T2
Authority
DE
Germany
Prior art keywords
tnf
tnfalpha
suppression
therapy
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69726878T
Other languages
English (en)
Other versions
DE69726878D1 (de
Inventor
Marc Feldmann
Anne-Marie Aline Miche Malfait
Debra Maree Butler
Fionula Mary Brennan
Ravinder Nath Maini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON
Kennedy Trust for Rheumatology Research
Original Assignee
KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON, Kennedy Institute of Rheumotology filed Critical KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON
Application granted granted Critical
Publication of DE69726878D1 publication Critical patent/DE69726878D1/de
Publication of DE69726878T2 publication Critical patent/DE69726878T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69726878T 1996-11-15 1997-11-17 UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE Expired - Lifetime DE69726878T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74997996A 1996-11-15 1996-11-15
PCT/GB1997/003151 WO1998022137A1 (en) 1996-11-15 1997-11-17 SUPPRESSION OF TNF α AND IL-12 IN THERAPY

Publications (2)

Publication Number Publication Date
DE69726878D1 DE69726878D1 (de) 2004-01-29
DE69726878T2 true DE69726878T2 (de) 2004-10-21

Family

ID=25016019

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726878T Expired - Lifetime DE69726878T2 (de) 1996-11-15 1997-11-17 UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE

Country Status (9)

Country Link
US (1) US20070178099A1 (de)
EP (1) EP0936923B1 (de)
AT (1) ATE256476T1 (de)
AU (1) AU4959997A (de)
DE (1) DE69726878T2 (de)
DK (1) DK0936923T3 (de)
ES (1) ES2213209T3 (de)
PT (1) PT936923E (de)
WO (1) WO1998022137A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
WO2000041547A2 (en) * 1999-01-13 2000-07-20 The Rockefeller University Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
TR200102715T2 (tr) * 1999-03-25 2002-09-23 Knoll Gmbh Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE403437T1 (de) * 1999-12-14 2008-08-15 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
KR20020086540A (ko) * 2000-02-21 2002-11-18 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
WO2002013867A2 (en) 2000-08-10 2002-02-21 Cold Spring Harbor Laboratory Augmented cognitive training
US6881407B2 (en) * 2000-08-11 2005-04-19 Ashok Amin Method for treating hepatitis
EP1188438A1 (de) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen
EP1199074A1 (de) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
DE60331598D1 (de) * 2003-07-25 2010-04-15 Silanes Sa De Cv Lab Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
EP2274333A4 (de) 2008-03-18 2011-06-15 Abbott Lab Verfahren zur behandlung von psoriasis
BRPI0919545A2 (pt) * 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-18 e métodos de purificar os mesmos
CN104974251A (zh) * 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
RU2011120178A (ru) * 2008-10-20 2012-11-27 Эбботт Лэборетриз Антитела, которые связываются с il-12, и способы их очистки
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
RU2012114854A (ru) 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US8394593B2 (en) * 2010-02-12 2013-03-12 Trudeau Institute Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof
US8877212B2 (en) 2011-02-07 2014-11-04 Trudeau Institute Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
EP0610201B2 (de) * 1991-03-18 2007-09-26 New York University Für menschlichen tumornekrose-faktor spezifische monoklonale und chimäre antikörper
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
EP0759466B1 (de) * 1995-08-01 2005-12-28 F. Hoffmann-La Roche Ag Interleukin-12-beta-Rezeptoren mit niedriger Bindungsaffinität

Also Published As

Publication number Publication date
PT936923E (pt) 2004-04-30
WO1998022137A1 (en) 1998-05-28
US20070178099A1 (en) 2007-08-02
ATE256476T1 (de) 2004-01-15
AU4959997A (en) 1998-06-10
EP0936923B1 (de) 2003-12-17
DE69726878D1 (de) 2004-01-29
DK0936923T3 (da) 2004-04-26
ES2213209T3 (es) 2004-08-16
EP0936923A1 (de) 1999-08-25

Similar Documents

Publication Publication Date Title
ATE256476T1 (de) Unterdrückung von tnfalpha und il-12 in der therapie
DE68920529D1 (de) Blockcopolymere und Zusammensetzungen davon.
ZA913539B (en) Synergistic therapeutic compositions and methods
ATE330973T1 (de) Antagonisten von g protein-gekoppelten rezeptoren
ATE281840T1 (de) Behandlung von diarrhoe
ATE414517T1 (de) Verabreichung von injizierbarem antibiotikum in das ohr eines tieres
DE68918943D1 (de) Gewebeentzusammensetzung und verfahren.
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
EP0596962A4 (en) Therapeutic compositions and methods.
FR2658536B1 (fr) Compositions et procedes d'electrodeposition.
DE3852389D1 (de) Rissformungsverhütung in implantierten Prothesen.
IT1224847B (it) Per l'isolamento di apparecchiature apparecchio smorzatore di vibrazio sensibili ne, in particolare da pavimento,
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ES2036526T3 (es) Composiciones de interferon.
IT8921128A0 (it) Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano.
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
HUP0002304A2 (hu) Állatok májából kivonható fehérjék alkalmazása tumor nekrózis faktor túltermelődéssel járó kóros állapotok kezelésére használható gyógyászati készítmények előállítására
ITRM920305A1 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
FR2542744B2 (fr) 3',5'-diarabinosides, leur preparation et leur application en therapeutique
IT9003692A0 (it) Dispositivo per l' assemblaggio di pannelli di mobili in genere.
IT1206319B (it) Dispositivo per lo scorrimento e l'ancoraggio di cassetti, cestelli corpi estraibili in genere, da mobili ed altro.
KR930022878U (ko) 가구의 고저수평 조절구
FR2665443B1 (fr) Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
DE69619522D1 (de) Therapie unter verwendung von lymphotoxin und thrombopoietin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition